Halozyme Therapeutics' stock surged 6.91% in pre-market trading on Tuesday.
The sharp rise comes after the biotechnology company reported better-than-expected first-quarter results. Halozyme posted adjusted earnings per share of $1.6, surpassing the IBES estimate of $1.53.
The positive earnings surprise triggered buying interest, extending gains from the post-market session where the stock was already trading higher following the results announcement.